AstraZeneca's Investigational Cancer Drug Disappoints In Late-Stage Lung Cancer Trial
AstraZeneca Plc (NASDAQ:AZN) shared detailed results from the TROPION-Lung01 Phase 3 of datopotamab deruxtecan (Dato-DXd) ...
AstraZeneca stock drops after lung cancer drug trial setback
London-listed AstraZeneca shares fell more than 5% on Tuesday after results from the company's lung cancer trials showed that ...
Investopedia12d
AstraZeneca Faces Setback From Lung Cancer Drug's Disappointing Trial Results
A Phase 3 trial found AstraZeneca's experimental lung cancer drug datopotamab deruxtecan did not significantly improve patients' overall survival rates. The results from the trial showed that ...
The Financial Times12d
AstraZeneca shares hit by lung cancer drug trial results
Shares in AstraZeneca dropped nearly 5 per cent on Tuesday after its failure to hit a target in trials for a ...
Becker's Hospital Review12d
AstraZeneca lung cancer drug fails trial
AstraZeneca's lung cancer drug datopotamab deruxtecan, also called Dato-DXd, failed to show a significant benefit to overall survival when compared to standard chemotherapy drug docetaxel ...
ThePrint11d
Months after import duty waiver, GST slashed on same 3 anti-cancer drugs. Why this is little relief
a particularly aggressive type of breast cancer. Earlier this year, the Drug Controller General of India (DCGI) also ...
Reuters13d
AstraZeneca says lung cancer drug trial shows no significant improvement in overall survival
LONDON, Sept 9 (Reuters) - Detailed results from one of AstraZeneca's (AZN.L), opens new tab key lung cancer trials released on Monday showed that its experimental precision drug did not ...
Benzinga.com12d
AstraZeneca's Investigational Cancer Drug Disappoints In Late-Stage Lung Cancer Trial
Also Read: AstraZeneca In Trouble For Employee Detentions in China Over Illegal Activities. Dato-DXd is an engineered TROP2-directed DXd antibody-drug conjugate ... on Lung Cancer (WCLC), the ...